Nureca LimitedQ2 FY27 Results & Financial Update
Nureca Limited: Q2 FY27 consolidated results and company financials – revenue ₹58.53 Cr, PAT ₹3.07 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Find an answer
Ask this result
Chart · Market context
Nureca price & chart
Quarter overview
Quarterly earnings analysis
Nureca Limited delivered a consolidated revenue from operations of ₹58.53 crore for the second quarter ended September 30, 2026, marking a robust expansion over the previous quarter's ₹40.34 crore and the ₹37.74 crore reported in the corresponding period of the previous year. Management highlighted in the earnings release that this performance represents the company's highest quarterly revenue in twenty quarters.
Operating expansion during the quarter was underpinned by broad-based demand across multiple commercial channels, with particular strength noted in e-commerce, quick-commerce platforms, and offline distribution trade. E-commerce channels continued to form the core of the revenue mix, accounting for approximately 88% of total sales during the period.
Cost structures remained disciplined as revenue expanded faster than operating overheads. Employee benefit expenses were reported at ₹4.11 crore, reflecting a stable workforce cost base relative to the top-line growth. Total expenses for the quarter aggregated to ₹54.36 crore, encompassing material consumption, inventory movements, and other operating expenses.
The company maintained a clean balance sheet structure with minimal long-term debt liabilities, positioning working capital investments to support upcoming seasonal demand. Total equity stood at ₹187.88 crore as of September 30, 2026, supported by strong retained reserves and capital allocations toward inventory positioning.
Cash flow statements for the half-year period ended September 30, 2026, indicated operating cash outflows of ₹125.38 crore, primarily driven by seasonal working capital adjustments including inventory build-up and trade receivable movements ahead of festive and winter demand cycles. Capital expenditures for the half-year included ₹21.40 crore directed toward property, plant, equipment, intangible assets, and capital advances.
01 · Business model
What does Nureca do?
Nureca Limited is a digital-first consumer healthcare and wellness products company operating prominent brands including Dr Trust, Dr Physio, and Trumom. Its product portfolio spans home diagnostics, fitness and body metrics, massage therapy, orthopaedic support, mother and baby care, and home wellness items.
The company distributes its products across India through a multi-channel network comprising online marketplaces, quick-commerce platforms, dedicated direct-to-consumer digital channels, and offline retail trade.
Nureca integrates hardware devices with software solutions such as the Dr Trust 360 platform, which links smart medical devices with health data tracking and personalised wellness insights.
The operating model leverages outsourced contract manufacturing alongside an expanding proprietary manufacturing footprint in Punjab, supporting scalable distribution across domestic digital and retail channels.
02 · Historical context
What shaped the business before this quarter
During the previous financial year, the company filed a Scheme of Merger by Absorption to amalgamate its wholly-owned subsidiary, Nureca Technologies Private Limited, with the parent company, with a proposed appointed date of April 1, 2025, pending final regulatory and NCLT sanctions.
The company has progressively built its digital and offline presence around core wellness brands including Dr Trust for diagnostics, Dr Physio for orthopaedics and fitness, and Trumom for mother and child care.
03 · Financial snapshot
Current quarter vs the two useful baselines
| Metric | Q2 FY27 | Year-ago | Previous quarter |
|---|---|---|---|
| Revenue from operations | ₹58.53 Cr | ₹37.74 Cr | ₹40.34 Cr |
| Total income | ₹59.88 Cr | ₹40.06 Cr | ₹42.16 Cr |
| Profit before tax | ₹5.52 Cr | ₹4.60 Cr | ₹4.43 Cr |
| Profit after tax | ₹3.07 Cr | ₹3.63 Cr | ₹3.07 Cr |
| EPS | ₹4.25 | ₹3.63 | ₹3.21 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 5.2% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 9.4% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹1.35 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Offline retail trade recorded significant gains, reflecting deeper market penetration and wider availability across pharmacy and retail counters.
What drove margins
Operating profit expanded ahead of revenue growth, benefiting from a largely fixed employee and administrative cost base as revenue scaled.
Employee benefit expenses remained tightly managed at ₹4.11 crore for the quarter, declining as a proportion of total revenue compared to preceding periods.
Realisation levels were supported by a favorable product mix leaning toward higher-margin smart home healthcare devices and diagnostics.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The group operates in a single reportable business segment, 'Home healthcare and wellness products', in accordance with Ind AS 108 standards.
Geography and market mix
Operations are primarily centered in India, supplemented by a US subsidiary (Nureca INC) which handles international market activities and compliance.
06 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
The company is expanding its manufacturing base in Punjab focused on producing medical devices, healthcare consumables, and hygiene products to support internal supply chains.
Projects, capex and execution
For the half-year ended September 30, 2026, payments for the purchase of property, plant, equipment, intangible assets, and capital advances totaled ₹21.39 crore, alongside ₹5.34 crore reported under capital work in progress.
07 · Strategy & new businesses
How the company is trying to change its growth mix
The Dr Trust 360 platform connects the company's smart health devices with user health data collection and personalised wellness insights, enhancing customer engagement and brand loyalty.
08 · Reported developments
What changed operationally
Quarterly revenue reached ₹58.53 crore, representing the highest quarterly top-line figure recorded by the company in the last 20 quarters.
Operating profit for the quarter grew to ₹5.23 crore, marking the highest operating profit level achieved in 19 consecutive quarters.
09 · Pressure points & risks
What is not going smoothly
Inventory accumulation and receivables expansion ahead of peak trading seasons led to temporary operating cash outflows during the half-year period.
10 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Working capital increased during the half-year period due to deliberate inventory buildup and channel positioning ahead of the upcoming festive and winter seasons.
Net cash outflow from operating activities for the half-year ended September 30, 2026, was ₹125.38 crore, impacted by working capital adjustments including an increase in inventories and trade receivables.
Capital allocation & funding
The company maintains a debt-free capital structure with minimal long-term borrowings and strong equity reserves totaling ₹187.88 crore.
11 · Beyond the numbers
What changed beyond the numbers
Executive Leadership
The financial results and press release were authorized and signed by Saurabh Goyal, Chairman and Managing Director of Nureca Limited.
12 · Previous-quarter changes
What changed since the previous quarter
Revenue from operations rose from ₹40.34 crore in Q1 FY27 to ₹58.53 crore in Q2 FY27, reflecting seasonal pick-up and channel expansion.
13 · Key Q&A
The quarter, answered directly
What does Nureca do?
Nureca Limited is a digital-first consumer healthcare and wellness products company operating prominent brands including Dr Trust, Dr Physio, and Trumom. Its product portfolio spans home diagnostics, fitness and body metrics, massage therapy, orthopaedic support, mother and baby care, and home wellness items.
What is the clearest takeaway from Q2 FY27?
Nureca Limited delivered a consolidated revenue from operations of ₹58.53 crore for the second quarter ended September 30, 2026, marking a robust expansion over the previous quarter's ₹40.34 crore and the ₹37.74 crore reported in the corresponding period of the previous year. Management highlighted in the earnings release that this performance represents the company's highest quarterly revenue in twenty quarters.
What drove revenue or demand?
Offline retail trade recorded significant gains, reflecting deeper market penetration and wider availability across pharmacy and retail counters.
What mattered most for margins or profitability?
Operating profit expanded ahead of revenue growth, benefiting from a largely fixed employee and administrative cost base as revenue scaled.
What changed operationally beyond the headline numbers?
The company is expanding its manufacturing base in Punjab focused on producing medical devices, healthcare consumables, and hygiene products to support internal supply chains.
What are the main pressure points disclosed for the quarter?
Inventory accumulation and receivables expansion ahead of peak trading seasons led to temporary operating cash outflows during the half-year period.
14 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
15 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Festive Season Demand Conversion: Monitor the sell-through of inventory built up during the half-year across online and offline channels during the festive and winter retail period.
- 02
Punjab Facility Commissioning: Track the execution progress and commercial commencement milestones of the expanded manufacturing facility in Punjab.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.
